Marshall Wace North America’s Evogene EVGN Stock Holding History

Marshall Wace North America’s Portfolio EVGN Stock Details EVGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-3,961	Closed	-$200K	–	1545
2021 Q1	$200K	Buy	+3,961	New	+$245K	﹤0.01%	1411

Other funds holding EVGN

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Marshall Wace North America's EVGN Position: Q2 2021 in Review

Marshall Wace North America sold out of Evogene (EVGN) in Q2 2021, closing a stake of 3,961 shares — an estimated $200K sold.

Marshall Wace North America first reported a position in EVGN in Q1 2021 and held it in 1 quarter. The position peaked at $200K in Q1 2021. 42 funds tracked by Wall St. Rank hold EVGN as of Q2 2021.

Marshall Wace North America reported no remaining Evogene position as of Q2 2021 after selling out during the quarter.
Marshall Wace North America sold 3,961 Evogene shares in Q2 2021, an estimated $200K.
Marshall Wace North America first reported a position in Evogene in Q1 2021 and held it in 1 quarter.
Marshall Wace North America's Evogene position peaked at $200K in Q1 2021.
42 funds tracked by Wall St. Rank held Evogene as of Q2 2021.

Based on Marshall Wace North America's 13F filing for Q2 2021, filed 13 Aug 2021.